Summary
This review, published in MedComm in 2025, synthesises current evidence on the pathogenesis of gut microbiota dysbiosis and its role in driving a spectrum of human diseases. It likely examines disruptions to microbial diversity and community structure, tracing mechanistic links to conditions such as inflammatory bowel disease, metabolic syndrome, and potentially neurological or immune-mediated disorders. The paper is also expected to evaluate preventive and therapeutic approaches, including dietary interventions, probiotic supplementation, and microbiome-targeted therapies.
UK applicability
Whilst this review is international in scope, its findings are broadly applicable to UK public health and clinical practice, given the high prevalence of dysbiosis-associated conditions such as obesity, type 2 diabetes, and inflammatory bowel disease in the UK population. The therapeutic and dietary strategies discussed may inform NHS clinical guidelines and public health nutrition policy.
Key measures
Microbiome composition and diversity indices; disease associations (e.g. metabolic, inflammatory, neurological conditions); therapeutic interventions (e.g. probiotics, prebiotics, faecal microbiota transplantation)
Outcomes reported
The paper likely reviews the pathogenic mechanisms underlying gut microbiota dysbiosis and its associations with a range of diseases, and evaluates current and emerging prevention and therapeutic strategies targeting the gut microbiome.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.